Cellevate AB, a biotech company developing the next generation of cell culture systems, announces that Dr Uwe Gottschalk has been elected as the Chair to its Board of Directors. The appointment follows the resignation of Mats Leifland, who served as Chairman of the Board until March 12, 2024.
Dr Gottschalk brings a wealth of experience within the field of biotechnology, boasting a distinguished career highlighted by significant achievements.
He currently serves as an Operating Partner at Keensight Capital. Dr. Gottschalk was awarded the Bioprocessing Lifetime Achievement Award (2021) after approximately 30 years in the biotech industry.
Previously, Dr. Gottschalk served as Group Vice President at Sartorius Stedim Biotech (2004-2014), with a global responsibility for all bioseparation-related process technology. Before joining Keensight Capital in 2022 he was Chief Technology Officer (2014-2017) and Chief Scientific Officer (2017-2021) at Lonza where he established and led the global Research and Technology organisation.
“Dr. Uwe Gottschalk's appointment as new Chairman marks a major milestone for Cellevate. With his extensive industry knowledge, decades of experience, and invaluable network connections, Dr. Uwe Gottschalk is well-suited to lead Cellevate into its next phase of growth and commercialization. I am confident that under Dr. Gottschalk's guidance, Cellevate will continue to thrive and achieve new heights of success,” says Mats Leifland, the departing Chairman of Cellevate's Board.
“I am thrilled to be Joining Cellevate as the new Chairman and to become part of such a dynamic and innovative company. I am looking forward to working with the Board of Directors and the Cellevate team to contribute to successful launch and commercialization of our unique nanotechnology in the field of bioprocessing” says Dr. Gottschalk.
